PL410665A1 - Inhibitory arginazy oraz ich zastosowania terapeutyczne - Google Patents

Inhibitory arginazy oraz ich zastosowania terapeutyczne

Info

Publication number
PL410665A1
PL410665A1 PL410665A PL41066514A PL410665A1 PL 410665 A1 PL410665 A1 PL 410665A1 PL 410665 A PL410665 A PL 410665A PL 41066514 A PL41066514 A PL 41066514A PL 410665 A1 PL410665 A1 PL 410665A1
Authority
PL
Poland
Prior art keywords
arginase
arginase inhibitors
therapeutical applications
compounds
activity
Prior art date
Application number
PL410665A
Other languages
English (en)
Inventor
Roman Błaszczyk
Jacek Olczak
Adam Gołębiowski
Original Assignee
Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością filed Critical Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL410665A priority Critical patent/PL410665A1/pl
Priority to PL15823405T priority patent/PL3240777T3/pl
Priority to EP15823405.4A priority patent/EP3240777B1/en
Priority to CA2973474A priority patent/CA2973474A1/en
Priority to US15/540,888 priority patent/US10329310B2/en
Priority to PCT/PL2015/050073 priority patent/WO2016108707A1/en
Priority to CN201580077041.3A priority patent/CN107406464B/zh
Priority to AU2015372690A priority patent/AU2015372690A1/en
Publication of PL410665A1 publication Critical patent/PL410665A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dentistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)

Abstract

Związki stanowią małocząsteczkowe środki terapeutyczne, które są mocnymi inhibitorami aktywności arginazy 1 i arginazy 2. Ujawniono też kompozycje farmaceutyczne i sposoby stosowania tych związków do leczenia lub zapobiegania chorobom lub stanom związanym z aktywnością arginazy.
PL410665A 2014-12-29 2014-12-29 Inhibitory arginazy oraz ich zastosowania terapeutyczne PL410665A1 (pl)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PL410665A PL410665A1 (pl) 2014-12-29 2014-12-29 Inhibitory arginazy oraz ich zastosowania terapeutyczne
PL15823405T PL3240777T3 (pl) 2014-12-29 2015-12-22 Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP15823405.4A EP3240777B1 (en) 2014-12-29 2015-12-22 Arginase inhibitors and their therapeutic applications
CA2973474A CA2973474A1 (en) 2014-12-29 2015-12-22 Arginase inhibitors and their therapeutic applications
US15/540,888 US10329310B2 (en) 2014-12-29 2015-12-22 Arginase inhibitors and their therapeutic applications
PCT/PL2015/050073 WO2016108707A1 (en) 2014-12-29 2015-12-22 Arginase inhibitors and their therapeutic applications
CN201580077041.3A CN107406464B (zh) 2014-12-29 2015-12-22 精氨酸酶抑制剂及其治疗用途
AU2015372690A AU2015372690A1 (en) 2014-12-29 2015-12-22 Arginase inhibitors and their therapeutic applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL410665A PL410665A1 (pl) 2014-12-29 2014-12-29 Inhibitory arginazy oraz ich zastosowania terapeutyczne

Publications (1)

Publication Number Publication Date
PL410665A1 true PL410665A1 (pl) 2016-07-04

Family

ID=56234474

Family Applications (2)

Application Number Title Priority Date Filing Date
PL410665A PL410665A1 (pl) 2014-12-29 2014-12-29 Inhibitory arginazy oraz ich zastosowania terapeutyczne
PL15823405T PL3240777T3 (pl) 2014-12-29 2015-12-22 Inhibitory arginazy oraz ich zastosowania terapeutyczne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15823405T PL3240777T3 (pl) 2014-12-29 2015-12-22 Inhibitory arginazy oraz ich zastosowania terapeutyczne

Country Status (7)

Country Link
US (1) US10329310B2 (pl)
EP (1) EP3240777B1 (pl)
CN (1) CN107406464B (pl)
AU (1) AU2015372690A1 (pl)
CA (1) CA2973474A1 (pl)
PL (2) PL410665A1 (pl)
WO (1) WO2016108707A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
AU2019229978B2 (en) 2018-03-05 2024-05-30 Arcus Biosciences, Inc. Arginase inhibitors
EP3765006A4 (en) 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
WO2019245890A1 (en) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
TWI828800B (zh) * 2018-11-16 2024-01-11 美商阿克思生物科學有限公司 Arg1及/或arg2之抑制劑
EP3897622B1 (en) 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
PH12021551902A1 (en) 2019-02-08 2022-08-01 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
AU2020293645A1 (en) 2019-06-14 2021-12-23 Rijksuniversiteit Groningen Novel arginase inhibitors
WO2021014380A1 (en) * 2019-07-23 2021-01-28 Astrazeneca Ab Arginase inhibitors and methods of use thereof
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
CA2669300A1 (en) 2006-11-21 2008-05-29 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
LT2389352T (lt) 2009-01-26 2019-06-10 The Trustees Of The University Of Pennsylvania Arginazės inhibitoriai ir naudojimo būdai
SG10201503168VA (en) 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
CA2824599C (en) 2010-12-31 2020-03-10 Astrazeneca Uk Limited Arginase inhibitors and methods of use thereof
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
CN104540836B (zh) 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物

Also Published As

Publication number Publication date
WO2016108707A1 (en) 2016-07-07
CN107406464B (zh) 2019-03-19
CN107406464A (zh) 2017-11-28
US10329310B2 (en) 2019-06-25
CN107406464A8 (zh) 2018-01-12
AU2015372690A1 (en) 2017-07-27
CA2973474A1 (en) 2016-07-07
PL3240777T3 (pl) 2019-10-31
EP3240777B1 (en) 2019-07-24
EP3240777A1 (en) 2017-11-08
US20180009830A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX391981B (es) Derivados de benzooxazol como inmunomoduladores.
MX385332B (es) Moduladores de ror-gamma.
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
NI201600071A (es) Compuestos de inhibidor de autotaxina
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX343534B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
PH12017501095A1 (en) Piperidine derivatives as hdac1/2 inhibitors
ZA201904522B (en) Heterocyclic inhibitors of mct4
EA201990400A1 (ru) Соединения и композиции и их применение
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX394452B (es) Inhibicion de la actividad de olig2.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида